Single Genome-editing Strategy Can Help Treat Multiple Disorders

Gene-Editing Breakthrough: A Shot at Cross-Disease Therapy?

Nonsense mutations—single faulty letters in our DNA—are responsible for nearly 25% of all known genetic disorders. These mutations function as molecular "stop signs" that prematurely halt protein production, leading to catastrophic consequences for body functions. For years, each disorder caused by such mutations required laborious, expensive, and disorder-specific solutions. A new methodology, Prime-Editing-mediated Readthrough of premature termination codons (PERT), published in Nature, may signal a departure from this piecemeal approach. PERT’s claim of a single genome-editing strategy applicable to multiple disorders is undeniably significant. But can a broad-spectrum cure live up to its promise in a landscape fraught with scientific, regulatory, and ethical challenges?

The Science of PERT: An Institutional Primer

The concept of PERT hinges on reprogramming the cell’s own mechanisms to ignore premature stop signals in the genome. Unlike existing treatments, which typically aim to address a single disease, PERT works by making the genetic machinery "read through" the faulty instructions caused by nonsense mutations. This enables protein synthesis to continue uninterrupted, resulting in functional proteins.

Prime Editing itself relies on cutting-edge molecular tools developed over the past two decades, such as CRISPR-based systems. However, PERT advances this by introducing what researchers describe as a gene-agnostic strategy. Rather than targeting the specific genetic sequence for each distinct disorder, PERT could theoretically address any nonsense mutation-based disease, dramatically reducing treatment timelines and costs. This is a vital threshold in the field of genomic medicine, where single-disease therapies sometimes require years of testing under stringent regulatory oversight before being approved.

Policy Architecture: A Glaring Void

Yet, beneath the scientific enthusiasm lies a stark vacuum on the policy front. India, despite its burgeoning biotechnology sector, lacks a cohesive framework to govern gene-editing techniques like PERT. The Environment Protection Act, 1986, under which biotech research is loosely governed, provides an outdated and fragmented legal base for such cutting-edge interventions. Regulatory bodies, such as the Genetic Engineering Appraisal Committee (GEAC), are equipped to handle agricultural biotech but fall short of oversight for human germline or somatic therapies. Moreover, no specific budgetary allocations exist for scaling genome-editing research under India's flagship health initiatives like Ayushman Bharat.

India currently spends a paltry 0.7% of its GDP on health research. Genomic technologies, inherently expensive and resource-intensive, are poorly aligned with this fiscal constraint. Without immediate policy attention, the financial and infrastructural gaps threaten to widen, relegating tools like PERT to the private sector or imported solutions from advanced economies.

Ground-Level Realities: The Innovation-to-Access Gap

Globally, the costs of gene-based therapies bear an unsettling pattern. The average treatment price for CRISPR-based interventions, for instance, exceeds $1 million per patient in the United States. If PERT claims global clinical success, can Indian public health systems absorb the innovation? This question is particularly pressing given India's entrenched inequities in health access. Government hospitals can barely deliver basic therapies, let alone invest in multimillion-dollar precision medicine tools.

The earlier excitement around CRISPR in India reflects a cautionary tale. Despite its rapid ascension as a revolutionary tool post-2009, India’s contribution to commercial pipeline applications of CRISPR has remained minimal. Policies aimed at gene-editing research have often faltered due to capacity constraints in state-run labs and insufficient public-private collaboration. What the PERT announcement underscores is a reinforced commitment to identifying funding mechanisms—not piecemeal investments but sustainable pipelines through bodies such as the Department of Biotechnology (DBT).

The Ethical Minefield

The irony here is that the technological simplicity of newer genome-editing methods like PERT makes them more accessible—not just to innovators, but to actors less bound by ethical or safety regulations. PERT, designed for somatic applications to treat genetic disorders in living patients, is a non-heritable intervention. But where does the line between somatic and germline applications blur? PERT’s underlying Prime Editing technology could theoretically also alter germline cells (i.e., reproductive DNA), raising the spectre of heritable genetic modifications—a domain fraught with ethical dilemmas about consent and intergenerational impact. This scenario mirrors China’s controversial use of CRISPR to create genetically modified babies in 2018, an incident that drew global outrage and led to tightening regulatory frameworks worldwide.

Lessons from the European Model

Europe offers a useful counterpoint. The European Medicines Agency (EMA) has developed detailed frameworks for precision medicine, balancing innovation funding with strict ethical controls. The EU’s Horizon Europe program allocates €95 billion for research and innovation between 2021 and 2027, with a specific emphasis on health technology. Dedicated funding for genome editing research ensures that technologies like PERT reach the point of affordability and are rigorously safety-tested before deployment. Comparatively, India’s policy paralysis and underfunding of health innovation cast doubts on whether it can keep pace with such global developments.

Structural Limitations and the Path Ahead

The success of PERT in India hinges on several moving parts. First, it demands legal recognition through a robust regulatory framework. Second, it relies on unprecedented levels of public health investment—the National Health Policy 2017 target of 2.5% GDP spending on healthcare must translate into concrete funds for genomic technologies.

Additionally, equitable access remains a major unsolved dilemma. Without systematic public-private partnerships, tools like PERT will remain limited to niche, urban private-sector hospitals. The wider socio-economic inequality in healthcare access, evident from poor rural infrastructure and lack of genetic testing labs in smaller towns, suggests that any implementation of PERT would initially skew toward privileged populations.

To institutionalise genome-based therapies, monitoring mechanisms should be strengthened. An independent scientific advisory council on genomic technologies, distinct from agricultural or environmental trial bodies, is urgently needed. Success indicators would also include PERT’s clinical uptake: How many diseases can it consistently address? How is side-effect risk communicated clinically? Crucially, integration with universal health systems like Ayushman Bharat must be prioritised to avoid turning genome editing into a luxury science.

Conclusion

While the promise of PERT as a panacea for nonsense mutation-based disorders is compelling, translating laboratory triumphs into public health gains is never straightforward. India must learn from its past lapses in biotech policy, address institutional deficiencies, and close the gap between high-tech ambition and grassroots realities. The genomic revolution will advance with or without India—our choice lies in how well-prepared we are to catch up.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions